Table 3. Adverse events.

	Cohort
	1		2		3
	Number of subjects	Number of events	Number of subjects	Number of events	Number of subjects	Number of events
Adverse drug reaction
Number (%) of subjects	2 (66.7)	5	1 (33.3)	1	1 (33.3)	1
Musculoskeletal and connective tissue disorder
Myalgia	1 (33.3)	3	0 (0.0)	0	1 (33.3)	1
General disorders and administration site conditions
Pyrexia	0 (0.0)	0	1 (33.3)	1	0 (0.0)	0
Fatigue	1 (33.3)	1	0 (0.0)	0	0 (0.0)	0
Skin and subcutaneous tissue disorder
Blister	1 (33.3)	1	0 (0.0)	0	0 (0.0)	0
Serious treatment-emergent adverse event
Number (%) of subjects	2 (66.7)	5	3 (100.0)	8	1 (33.3)	1
Respiratory, thoracic, and mediastinal disorders
Pleural effusion	0 (0.0)	0	2 (66.7)	4	0 (0.0)	0
Dyspnea	1 (33.3)	2	0 (0.0)	0	0 (0.0)	0
Pneumothorax	1 (33.3)	1	0 (0.0)	0	0 (0.0)	0
Infections and infestations
Pneumonia	1 (33.3)	1	0 (0.0)	0	0 (0.0)	0
Wound infection	0 (0.0)	0	1 (33.3)	1	0 (0.0)	0
Nervous system disorders
Dizziness	0 (0.0)	0	1 (33.3)	1	0 (0.0)	0
Headache	1 (33.3)	1	0 (0.0)		0 (0.0)	0
Blood and lymphatic system disorders
Febrile neutropenia	0 (0.0)	0	1 (33.3)	1	0 (0.0)	0
General disorders and administration site conditions
Chest pain	0 (0.0)	0	1 (33.3)	1	0 (0.0)	0
Hepatobiliary disorders
Bile duct obstruction	0 (0.0)	0	0 (0.0)	0	1 (33.3)	1